Labcorp beats quarterly estimates on diagnostic test demand

Reuters

2024/10/24

Oct 24 (Reuters) - Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.

Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.

The company, however, cut the top-end of its 2024 adjusted profit forecast to $14.70 per share from $14.90, due to an about 15 cent impact from weather-related disruptions, keeping the low-end at $14.30.

Analysts on average see profit for the period to be $14.56 per share, according to data compiled by LSEG.

The company's sales rose 7.4% to $3.28 billion from a year earlier, beating analysts' average estimate of $3.26 billion.

On an adjusted basis, Labcorp reported a third-quarter profit of $3.50 per share, above estimates of $3.48 per share.

(Reporting by Puyaan Singh in Bengaluru; Editing by Maju Samuel)

((Puyaan.Singh@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2477856736"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2477856736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2477856736?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-24 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477856736","market":"us","top_or_hot":-1,"title":"Labcorp beats quarterly estimates on diagnostic test demand","media":"Reuters","content":"<html><body><p>Oct 24 (Reuters) - Laboratory operator Labcorp    on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.</p><p>   Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.</p><p>   The company, however, cut the top-end of its 2024 adjusted profit forecast to $14.70 per share from $14.90, due to an about 15 cent impact from weather-related disruptions, keeping the low-end at $14.30.</p><p>   Analysts on average see profit for the period to be $14.56 per share, according to data compiled by LSEG.</p><p>       The company's sales rose 7.4% to $3.28 billion from a year earlier, beating analysts' average estimate of $3.26 billion.</p><p>   On an adjusted basis, Labcorp reported a third-quarter profit of $3.50 per share, above estimates of $3.48 per share.</p><p> (Reporting by Puyaan Singh in Bengaluru; Editing by Maju Samuel)</p><p>((Puyaan.Singh@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp beats quarterly estimates on diagnostic test demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp beats quarterly estimates on diagnostic test demand\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-10-24 19:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>Oct 24 (Reuters) - Laboratory operator Labcorp    on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.</p><p>   Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.</p><p>   The company, however, cut the top-end of its 2024 adjusted profit forecast to $14.70 per share from $14.90, due to an about 15 cent impact from weather-related disruptions, keeping the low-end at $14.30.</p><p>   Analysts on average see profit for the period to be $14.56 per share, according to data compiled by LSEG.</p><p>       The company's sales rose 7.4% to $3.28 billion from a year earlier, beating analysts' average estimate of $3.26 billion.</p><p>   On an adjusted basis, Labcorp reported a third-quarter profit of $3.50 per share, above estimates of $3.48 per share.</p><p> (Reporting by Puyaan Singh in Bengaluru; Editing by Maju Samuel)</p><p>((Puyaan.Singh@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LH","symbol_name":"徠博科","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2477856736","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477856736","pubTimestamp":1729767813,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 24  - Laboratory operator Labcorp    on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.   Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.   The company, however, cut the top-end of its 2024 adjusted profit forecast to $14.70 per share from $14.90, due to an about 15 cent impact from weather-related disruptions, keeping the low-end at $14.30.   Analysts on average see profit for the period to be $14.56 per share, according to data compiled by LSEG.       The company's sales rose 7.4% to $3.28 billion from a year earlier, beating analysts' average estimate of $3.26 billion.   On an adjusted basis, Labcorp reported a third-quarter profit of $3.50 per share, above estimates of $3.48 per share. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LH":"徕博科","BK4196":"保健护理服务","BK4550":"红杉资本持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD"},"translate_title":"Labcorp的诊断测试需求超出季度预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9},"content_text":"Oct 24 (Reuters) - Laboratory operator Labcorp    on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.   Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.   The company, however, cut the top-end of its 2024 adjusted profit forecast to $14.70 per share from $14.90, due to an about 15 cent impact from weather-related disruptions, keeping the low-end at $14.30.   Analysts on average see profit for the period to be $14.56 per share, according to data compiled by LSEG.       The company's sales rose 7.4% to $3.28 billion from a year earlier, beating analysts' average estimate of $3.26 billion.   On an adjusted basis, Labcorp reported a third-quarter profit of $3.50 per share, above estimates of $3.48 per share. (Reporting by Puyaan Singh in Bengaluru; Editing by Maju Samuel)((Puyaan.Singh@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}